Rheumesser

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rheumesser

Quick Facts

Property Description
Active Ingredients Five-component combination (Kebuzone, Dexamethasone, Lidocaine, Cyanocobalamin, Salicylamide-O-Acetic Acid)
Form Solution for injection (Ampoules)
Pharmacological Class Combination Anti-inflammatory / Analgesic
Common Use Acute pain and inflammation (musculoskeletal, nerve-related)
Origin Primarily synthetic (Austrian product, G.L. Pharma)

What Type of Medicine is Rheumesser?

Rheumesser is a specific brand-name combination drug manufactured by G.L. Pharma (Austria), formulated as an injectable solution typically administered intramuscularly. It is classified as a multi-component anti-inflammatory analgesic due to its blend of five active substances. This combination format is a key differentiator, as it merges a potent corticosteroid, an NSAID, a local anesthetic, and a B-vitamin, designed for a single, comprehensive therapeutic intervention. This multi-target approach is clinically recognized for providing effective relief in acute, severe pain scenarios, such as sudden flare-ups of neuritis or lumbago.


What is Rheumesser Made Of?

Rheumesser is unique due to its five-ingredient composition, focusing on suppressing inflammation, blocking pain, and supporting nerve health simultaneously. The main anti-inflammatory drivers are the synthetic corticosteroid Dexamethasone and the NSAID Kebuzone, a pyrazolidine derivative known for its anti-inflammatory and analgesic properties. Kebuzone is utilized in the management of inflammation associated with rheumatic disorders. This is paired with Lidocaine, a local anesthetic for immediate pain relief at the injection site, and Cyanocobalamin (Vitamin B12), which is included to support the maintenance of nerve tissue integrity.


What is the Goal of This Combination?

The overall goal of the Rheumesser combination is to provide a rapid and powerful resolution for acute pain and inflammation that has not responded adequately to simpler treatments. Unlike standard NSAIDs or single-steroid injections, this unique blend is positioned for situations demanding a swift, decisive effect in acute painful inflammatory processes. By addressing nerve irritation, immediate pain, and underlying swelling, the drug aims to break the cycle of acute, debilitating pain quickly.

What side effects are possible with Rheumesser?

Possible side effects and safety information

The official safety profile for this five-component injection is primarily derived from the established risks of its main active ingredients: the corticosteroid (Dexamethasone) and the NSAID/pyrazolidine derivative (Kebuzone). Regulatory authorities classify adverse reactions based on affected System-Organ Classes and their frequency of occurrence (e.g., Common, Rare, Not Known).

Official Regulatory Safety Classifications

Adverse reactions are documented across several systems, consistent with systemic steroid and NSAID exposure:

System-Organ Class (SOC) Examples of Officially Listed Adverse Reactions
Gastrointestinal Ulceration, perforation, and haemorrhage
Metabolism / Endocrine Hyperglycaemia, fluid retention, HPA axis suppression, Cushingoid features
Psychiatric Mood changes, anxiety, psychosis, sleep disturbances
Musculoskeletal Osteoporosis, pathological fractures, tendon rupture

Serious and Population-Specific Safety

Official labels identify certain events as Serious Adverse Reactions, including severe gastrointestinal bleeding, acute adrenal insufficiency (upon too rapid withdrawal), and potentially serious arterial thrombotic events associated with NSAIDs.

Regulatory documents also detail safety considerations for specific groups. The elderly are noted to have an increased frequency and severity of adverse effects, particularly gastrointestinal complications. For children and adolescents, there is a documented risk of growth retardation associated with the corticosteroid component.

Time-related safety patterns are explicitly stated: psychiatric reactions may appear at the start of treatment, while risks like osteoporosis and cataracts are associated with prolonged exposure over weeks or months.

Overdose and Emergency Response

Overdose and When to Seek Help

Rheumesser overdose involves the combined toxicological profiles of its potent active ingredients, primarily the local anesthetic (Lidocaine) and the anti-inflammatory agents (Kebuzone, Dexamethasone), as documented in regulatory prescribing information.

Officially Documented Manifestations

Overdose may present with serious symptoms affecting the Central Nervous System (CNS) and the Cardiovascular System. Documented CNS signs of Local Anesthetic Systemic Toxicity (LAST) include metallic taste, dizziness, tinnitus, blurred vision, and progressing to agitation and seizures. Severe cardiovascular manifestations can include hypotension, marked bradycardia, and life-threatening arrhythmias, culminating in cardiac arrest. The NSAID component can lead to symptoms like nausea, headache, and potential renal failure (oliguria/anuria). Acute Dexamethasone excess is primarily noted for minor changes in body fluids and electrolytes.

Emergency Actions Required

The regulatory guidance is explicit: Seek immediate medical attention for any suspected overdose. This requirement is strictly based on the documented risk of cardiac arrest and death associated with a delay in managing severe Lidocaine toxicity. Management is officially categorized as symptomatic and supportive. Hospital monitoring is required, focusing on continuous observation of vital signs and treating specific complications, such as the use of methylene blue for methemoglobinemia. Population-specific considerations note that elderly and acutely ill patients are at greater risk of toxic concentrations.

Therapeutic Uses of Rheumesser

What Rheumesser Treats: Main Uses and Benefits

Rheumesser is generally used to provide symptomatic relief for acute, severe painful inflammatory processes, particularly those involving the nervous and musculoskeletal systems. The medication is applied in clinical settings where supportive relief that assists in managing heightened symptom intensity is appropriate. It is indicated for short-term treatment of acute painful inflammatory processes in conditions such as rheumatic diseases, neuritis, cervical syndrome, ischialgia, and lumbago.

The medication is considered relevant when symptoms that interfere with daily functioning become temporarily overwhelming and require additional symptomatic assistance. It is commonly applied to address symptoms related to inflammatory or irritative states of peripheral nerves, such as radicular pain syndromes. This application supports patients during difficult episodes by easing distress and helps maintain a sense of stability when acute symptoms interfere with routine activities.


Quick Fact: Support for Acute Symptom Management
Typical Context Often used when symptoms intensify and supportive relief is needed.
Focus on Benefit Contributes to easing the overall symptom load and functional strain.
Areas of Support Symptoms linked to inflammatory or irritative states and severe pain.

Regulatory References

  1. Rheumesser® Product Information

Eligibility and Restrictions for Use

Who can and cannot use Rheumesser? — Official Regulatory Information

The eligibility profile for Rheumesser is defined by specific restrictions related to age and duration of use, based on official regulatory documents such as the German package leaflet.

Eligibility Scope and Restrictions

Classification Official Regulatory Rule
Populations Allowed Use is indicated for adults (patients aged 18 years and older).
Age-Related Rules Use is not established or approved for pediatric patients (children and adolescents).
Use Constraints The medicine must be limited to short-term treatment.
Eligibility Restriction Use is reserved only for the strictest indications, implying non-eligibility for non-severe or long-term conditions.
Contraindicated Groups Specific absolute contraindications are not detailed in general regulatory summaries.

Summary of Regulatory Constraints

Official documents strictly limit the use of Rheumesser to the adult population. This establishes a clear exclusion for all patients under 18 years of age. Furthermore, its use is severely constrained by duration, as it is only permitted for short-term treatment, and by clinical context, requiring it be reserved only for the most strictest clinical indications listed on the label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Rheumesser, based on its active components (an NSAID, a corticosteroid, and a local anesthetic), outlines specific drug-drug and drug-substance interaction patterns documented in official governmental sources.

Pharmacodynamic and Bleeding Risk

Co-administration with other NSAIDs or acetylsalicylic acid is documented to increase the risk of adverse gastrointestinal events, including bleeding, due to additive pharmacodynamic effects. Similarly, the NSAID component (Kebuzone) increases the formal risk of hemorrhage when combined with anticoagulants, such as Warfarin.

Metabolic and Exposure Alterations

Interactions that alter drug exposure are formally noted: CYP enzyme inhibitors (e.g., certain antifungals) can decrease the clearance of Dexamethasone and Lidocaine, potentially increasing their plasma concentrations. Conversely, CYP Inducers (e.g., Phenytoin) are stated to increase the metabolism of Dexamethasone, which may reduce the drug's exposure and efficacy.

Other Clinically Significant Interactions

  • Potassium-depleting agents (e.g., diuretics) increase the risk of low potassium levels (hypokalemia) due to the corticosteroid component.
  • Co-administration with antidiabetic agents may result in reduced blood glucose control.
  • Consumption of alcohol is documented to increase the risk of gastrointestinal irritation and bleeding.

Official labeling indicates that compromised hepatic or renal function may increase the severity of these interactions, requiring specific caution.

Mechanism of Action

Dual-Action Blockade of the Inflammatory Cascade

This mechanism involves a coordinated strategy for suppressing the molecular origins of the body's inflammatory response using two distinct components. Dexamethasone acts upstream by modulating gene expression to prevent the initial release of Arachidonic Acid via Phospholipase A2 ( PLA2) inhibition. Kebuzone and Salicylamide-O-Acetic Acid work downstream by inhibiting Cyclooxygenase ( COX) enzymes, blocking the synthesis of Prostaglandins. This synergistic, multi-level blockade leads to a comprehensive reduction in the synthesis of pro-inflammatory eicosanoids and modulation of cellular immune responses.


️ Immediate Interruption of Peripheral Nerve Signaling

The drug directly alters electrical signaling by using Lidocaine to block Voltage-Gated Sodium Channels ( VGSC) on peripheral nerve fibers. This physical blockade prevents the necessary sodium influx, halting the electrical action potential that transmits the signal. This interruption results in the abolition of impulse conduction in the affected peripheral fibers.


Metabolic Support for Neural Integrity

The final domain involves the supportive action of Cyanocobalamin ( B12), which functions as an essential cofactor in metabolic pathways necessary for nerve health. This mechanism supports the structural integrity of the myelin sheath and other crucial components of peripheral nerve tissue by participating in essential metabolic and methylation reactions.

Dosage and Administration Information

Official Administration Guidelines

Rheumesser is a combination product subject to specific instructions governing its use. This section outlines how the medication is administered based on standardized guidelines.

The use of Rheumesser is limited to adults and is intended exclusively for short-term treatment of acute processes.

Administration Scope Description
Route of Administration Intramuscular (IM) injection only.
Dosage Form Solution for injection (ampoule).
Standard Dosing Regimen One ampoule (3 mL) per administration.
Use Duration Short-term treatment only.

Dosing Frequency and Procedural Requirements

The frequency and procedural steps for administering Rheumesser are formally defined:

  • Frequency: The standard administration schedule is typically once daily. An alternate regimen allows for up to three injections per week (e.g., every two to three days), based on the acute needs of the condition.
  • Administration Setting: As a solution for injection, the medication is administered by a healthcare professional in a clinical setting (outpatient or inpatient).
  • Preparation: The solution is supplied ready for use, and no preparation requirements (such as dilution or mixing) are specified.

These instructions outline the standardized approach to using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has evaluated whether the compound was studied in relation to markers of inflammation. Research has explored the compound's use in conditions where inflammatory processes are a research focus. Studies have evaluated whether the compound is associated with changes in joint mobility and pain reduction. These initial trials were often small and short in duration.

  • Findings have varied regarding the duration of any observed changes in swelling, with some studies observing changes within the first month.
  • Studies have explored the relationship between the drug and the frequency of flare-ups, and researchers have examined whether changes were observed in immune markers.

Dosage and Administration Studies

Studies have examined this combination in the context of chronic conditions. Research has investigated the frequency of adverse events associated with this dosage in an elderly patient cohort. The compound was generally studied in daily dosage protocols.


Safety and Adverse Event Data

Research into this drug has included analysis of adverse event data, with specific focus on pre-existing heart conditions. No major adverse events were reported in the specific studies reviewed, but research indicates data on long-term evidence is still being collected.

  • Some trials reported that the frequency of adverse events was similar to that observed with placebo in most short-term trials.
  • Some studies have evaluated the speed of response to the drug.
  • Reported adverse events in the studies included instances of mild gastrointestinal upset.

Frequently Asked Questions (FAQ)

Common questions about Rheumesser (FAQ)

Q: How quickly should I expect to feel the effects of Rheumesser?

A: As an injection, the product is designed for a rapid effect. The local anesthetic component, Lidocaine, is designed to provide rapid onset of pain relief. The full therapeutic effect of the anti-inflammatory components may take a longer period to be fully observed.

Q: Can Rheumesser cause weight changes, and is it a common side effect?

A: Official regulatory information associated with the corticosteroid component (Dexamethasone) lists known side effects related to metabolism and the endocrine system. These effects can lead to fluid retention and changes associated with Cushingoid features, which may involve altered body fat distribution or weight gain.

Q: Will Rheumesser affect my immune system, and how?

A: Official information indicates the corticosteroid component has immunosuppressive properties. This action reduces the body's resistance, and official documents warn that this may increase the risk of infection.

Q: Is it normal to feel a bit nauseous when first starting Rheumesser?

A: Gastrointestinal adverse reactions are listed in official product information due to the presence of the NSAID component (Kebuzone). Nausea, alongside abdominal pain or other stomach upsets, is a known potential adverse effect.

Q: Can Rheumesser be taken with over-the-counter pain relievers like ibuprofen?

A: Official regulatory warnings caution against co-administering this product with other nonsteroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen. Combining them significantly increases the risk of severe gastrointestinal issues, such as bleeding.

Q: Does Rheumesser interact negatively with any common vitamins or supplements?

A: Regulatory information advises caution when using supplements, particularly those that may affect the metabolism of drugs, such as certain herbal products. It is important to inform your healthcare provider about all concurrent supplements.

Q: Can people with kidney issues use Rheumesser safely?

A: Regulatory documents indicate that the drug is either contraindicated or requires specific caution in people with severe kidney impairment. Pre-existing kidney conditions, particularly impairment, are noted as conditions requiring specific caution and close monitoring by a healthcare professional.

Q: What is the typical half-life of Rheumesser in the body?

A: Rheumesser is a combination product, and its components have different half-lives. The corticosteroid component has a relatively long biological half-life, while the local anesthetic component has a much shorter half-life. These factors determine the required dosing schedule.

Q: Is Rheumesser safe for people who have other chronic health conditions?

A: Official information lists specific precautions and contraindications related to many pre-existing chronic conditions, including diabetes, heart failure, and high blood pressure. The presence of these conditions requires close monitoring by a healthcare professional if the medication is administered.

Q: Is Rheumesser known to cause issues with sleep or insomnia?

A: Sleep disturbances and insomnia are listed as known adverse effects in official regulatory documents. These issues are associated with the corticosteroid component (Dexamethasone) and are categorized under psychiatric disorders.

Q: Can men or women taking Rheumesser have concerns about fertility?

A: Regulatory information states that the NSAID component is in a class of drugs known to potentially impair female fertility. For both men and women, any effects on reproductive ability must be discussed with a healthcare professional before use.

Q: Is Rheumesser an immunosuppressant, and what does that mean for catching colds?

A: The corticosteroid component has immunosuppressive properties. This reduces the body's natural defense against infection, meaning the risk of contracting infections, including common colds or other viruses, may be increased during treatment.

Q: Does Rheumesser affect my ability to drive or operate machinery?

A: Official warnings state that the medication may cause side effects, such as dizziness or changes in vision, that can impair your ability to drive safely or operate machinery. It is advised to be aware of how you react to the medication before engaging in these activities.

Q: Does Rheumesser have a generic version available, or is it brand-only?

A: Rheumesser is a specific brand-name formulation with a unique combination of five active components. Official regulatory registries list it under this specific brand name, and alternative generic equivalents for this precise multi-component product are not listed.

Q: Is the effect of Rheumesser reversible if I stop taking it?

A: The effects of the corticosteroid component on the body's hormone production (HPA axis suppression) are generally reversible. However, the drug must be withdrawn gradually and carefully by a healthcare professional to avoid serious complications like acute adrenal insufficiency.

Q: Can Rheumesser cause changes in mood or anxiety levels?

A: Yes, psychiatric disturbances are known adverse reactions associated with the corticosteroid component. Official side effect listings include mood changes, anxiety, depression, and, in rare instances, psychosis.

Q: Are headaches a frequent side effect of Rheumesser?

A: Headaches are listed as a potential adverse reaction in the official product information. This effect is associated with both the NSAID and corticosteroid components, with varying frequencies noted in clinical data.

Q: Why does Rheumesser need to be taken a certain way (e.g., with food or at a specific time)?

A: Rheumesser is administered as an intramuscular injection, not an oral product. The administration schedule (typically once daily or up to three times per week) is required to maintain the necessary concentration of the active substances and ensure therapeutic effectiveness while managing risk.

Q: What is the difference in how Rheumesser is given (e.g., pill vs. injection)?

A: Rheumesser is exclusively formulated and administered as a solution for intramuscular injection by a healthcare professional. This route is mandated in regulatory instructions to ensure the active components achieve rapid and sufficient systemic exposure.

Q: Does Rheumesser contain any common allergens, like gluten or lactose?

A: Official regulatory documents list all inactive ingredients (excipients). If you have known sensitivities to common allergens, you should review the specific list in the official package leaflet provided by your healthcare professional.

Q: Are there any known issues with Rheumesser and dental procedures?

A: Due to its systemic corticosteroid component, this product may affect your immune response and healing. It is essential to inform your dentist or surgeon that you are receiving this treatment before any major dental or surgical procedure.

Q: Can taking Rheumesser affect the results of other medical tests?

A: The corticosteroid component is known to potentially interfere with the results of certain medical tests, especially those used to evaluate endocrine (hormone) function. This should be disclosed to the clinician performing the test.

Q: Does the efficacy of Rheumesser decrease if I drink alcohol occasionally?

A: Official documents primarily warn that alcohol consumption significantly increases the risk of gastrointestinal irritation and bleeding when combined with this medication. While efficacy reduction is not typically cited, the risk profile is significantly altered.

Q: What are the restrictions for women who are trying to become pregnant while on Rheumesser?

A: Official information states that the drug is contraindicated (not allowed) during the third trimester of pregnancy. Furthermore, women who are planning pregnancy should avoid use of this medication, as risks are associated with the components.

Q: Is a metallic taste in the mouth sometimes reported with Rheumesser?

A: The local anesthetic component (Lidocaine) is known to potentially cause sensory disturbances, especially if higher concentrations enter the bloodstream. These effects can sometimes include a metallic taste or other unusual oral sensations.

Q: What should I do if I accidentally take two doses of Rheumesser close together?

A: The official product information includes a section on overdose that details the potential clinical signs and symptoms of exceeding the prescribed dose. You should seek immediate medical attention from your healthcare provider or emergency services.

Q: How important is it to take Rheumesser exactly as directed for it to work?

A: Strict adherence to the administration route and the schedule prescribed by the healthcare professional is essential. This is required both to maintain the product's therapeutic effect and to minimize the risk of serious side effects.

Q: Are there different strengths or formulations of Rheumesser available?

A: The official regulatory information specifies the exact composition and strength of the single available formulation, which is a 3 mL solution for injection. Alternative strengths or different dosage forms are not listed.

Q: Does Rheumesser have any known effects on cholesterol levels?

A: The corticosteroid component is associated with disturbances in the body's metabolism and endocrine system. Regulatory sources indicate these changes can include alterations to lipid (fats like cholesterol) and glucose (blood sugar) levels.

How should Rheumesser be stored and disposed of?

How to Store and Dispose of Rheumesser

The storage of Rheumesser solution for injection is strictly defined in the regulatory labeling to maintain stability. The ampoules must be stored in a refrigerator, at a temperature range of 2 C to 8 C. Protection from light is mandatory, requiring the product to be kept in the original outer packaging.

The label permits a stability exception, allowing the product to be stored at temperatures up to 25 C for a period not exceeding four weeks. It is strictly required to keep the medicine out of the sight and reach of children.

The ampoules are for single use only, and any residual solution must be discarded. Disposal of unused or expired Rheumesser must follow specific pharmaceutical waste procedures. The product must not be thrown away in household waste or wastewater; instead, the pharmacist should be consulted for proper disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rheumesser found in:

A-Z Index: